ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals (ENZN) announced on March 16, 2026 that it has extended the expiration date of its exchange offer to permit holders of Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. After the extension, the Offer now expires at 5:00 p.m., Eastern time, on March 19, 2026, unless further extended. The company attached a press release as Exhibit 99.1 to the Form 8‑K.

Key Details

• Offer extension announced: March 16, 2026; new expiration time/date: 5:00 p.m. ET on March 19, 2026.
• Security involved: Series C Non-Convertible Redeemable Preferred Stock exchanged for Enzon common stock (par value $0.01).
• Related transaction: Enzon has filed a Form S-4 registration statement for the proposed merger with Viskase Companies, Inc.; the Registration Statement (prospectus/consent solicitation/offer to exchange) is available at sec.gov and on Enzon’s website.
• The filing includes standard forward‑looking statements and risk disclosures about the proposed merger, timing, approvals, and other closing conditions.

Why It Matters

• The extension gives Series C holders additional time to decide whether to convert preferred shares into common stock, which can affect Enzon’s share count and ownership structure if many holders accept the exchange.
• This action is part of the broader transaction process tied to Enzon’s proposed merger with Viskase; investors should review the Form S-4 for combined-company financials and the listed risks before drawing conclusions.
• The filing is a factual disclosure of the extension and related public materials; it does not itself change merger terms and the offer may be extended again or terminated depending on conditions.